| [1] |
Lian H, Gong S Q, Li M, et al. Prevalence and clinical characteristics of PDX1 variant induced diabetes in Chinese early-onset type 2 diabetes[J]. J Clin Endocrinol Metab, 2023, 108(12): e1686-1694.
|
| [2] |
Shields B M, Hicks S, Shepherd M H, et al. Maturity-onset diabetes of the young(MODY): how many cases are we missing?[J]. Diabetologia, 2010, 53(12): 2504-2508. DOI: 10.1007/s00125-010-1799-4.
|
| [3] |
TATTERSALL R B. Mild familial diabetes with dominant inheritance[J]. Q J Med, 1974, 43(170): 339-357.
|
| [4] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. DOI: 10.1038/gim.2015.30.
|
| [5] |
徐勇,胡承,杨涛, 等. 青少年起病的成人型糖尿病筛查与诊治专家共识[J]. 中华糖尿病杂志, 2022, 14(5): 423-432.
|
| [6] |
|
| [7] |
|
| [8] |
Njølstad P R, Molven A. To test, or not to test: time for a MODY calculator?[J]. Diabetologia, 2012, 55(5): 1231-1234. DOI: 10.1007/s00125-012-2514-4.
|
| [9] |
Majidi S, Fouts A, Pyle L, et al. Can biomarkers help target maturity-onset diabetes of the young genetic testing in antibody-negative diabetes?[J]. Diabetes Technol Ther, 2018, 20(2): 106-112. DOI: 10.1089/dia.2017.0317.
|
| [10] |
Roehlen N, Hilger H, Stock F, et al. 17q12 deletion syndrome as a rare cause for diabetes mellitus type MODY5[J]. J Clin Endocrinol Metab, 2018, 103(10): 3601-3610. DOI: 10.1210/jc.2018-00955.
|
| [11] |
Bell G I, Xiang K S, Newman M V, et al. Gene for non-insulin-dependent diabetes mellitus(maturity-onset diabetes of the young subtype)is linked to DNA polymorphism on human chromosome 20q[J]. Proc Natl Acad Sci USA, 1991, 88(4): 1484-1488. DOI: 10.1073/pnas.88.4.1484.
|
| [12] |
Chandra V, Huang P X, Potluri N, et al. Multidomain integration in the structure of the HNF-4α nuclear receptor complex[J]. Nature, 2013, 495(7441): 394-398. DOI: 10.1038/nature11966.
|
| [13] |
Kind L, Molnes J, Tjora E, et al. Molecular mechanism of HNF-1A-mediated HNF4A gene regulation and promoter-driven HNF4A-MODY diabetes[J]. JCI Insight, 2024, 9(11): e175278.
|
| [14] |
Pearson E R, Pruhova S, Tack C J, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection[J]. Diabetologia, 2005, 48(5): 878-885. DOI: 10.1007/s00125-005-1738-y.
|
| [15] |
Pearson E R, Boj S F, Steele A M, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene[J]. PLoS Med, 2007, 4(4): e118.
|
| [16] |
Pearson E R, Starkey B J, Powell R J, et al. Genetic cause of hyperglycaemia and response to treatment in diabetes[J]. Lancet, 2003, 362(9392): 1275-1281.
|
| [17] |
Fajans S S, Brown M B. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young[J]. Diabetes Care, 1993, 16(9): 1254-1261. DOI: 10.2337/diacare.16.9.1254.
|
| [18] |
Müssig K. Novel treatment options in patients with maturity-onset diabetes of the young[J]. Exp Clin Endocrinol Diabetes, 2025, 133(1): 51-58. DOI: 10.1055/a-2436-7723.
|
| [19] |
Marso S P, Daniels G H, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2016, 375(4): 311-322. DOI: 10.1056/NEJMoa1603827.
|
| [20] |
Marso S P, Bain S C, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2016, 375(19): 1834-1844. DOI: 10.1056/NEJMoa1607141.
|
| [21] |
Broome D T, Pantalone K M, Kashyap S R, et al. Approach to the patient with MODY-monogenic diabetes[J]. J Clin Endocrinol Metab, 2021, 106(1): 237-250. DOI: 10.1210/clinem/dgaa710.
|